134 related articles for article (PubMed ID: 10081632)
1. Screening for basiliximab exposure-response relationships in renal allotransplantation.
Kovarik JM; Moore R; Wolf P; Abendroth D; Landsberg D; Soulillou JP; Gerbeau C; Schmidt AG
Clin Transplant; 1999 Feb; 13(1 Pt 1):32-8. PubMed ID: 10081632
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.
Kovarik JM; Kahan BD; Rajagopalan PR; Bennett W; Mulloy LL; Gerbeau C; Hall ML
Transplantation; 1999 Nov; 68(9):1288-94. PubMed ID: 10573065
[TBL] [Abstract][Full Text] [Related]
3. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
[TBL] [Abstract][Full Text] [Related]
4. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients.
Kovarik JM; Pescovitz MD; Sollinger HW; Kaplan B; Legendre C; Salmela K; Book BK; Gerbeau C; Girault D; Somberg K;
Clin Transplant; 2001 Apr; 15(2):123-30. PubMed ID: 11264639
[TBL] [Abstract][Full Text] [Related]
5. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
Kahan BD; Rajagopalan PR; Hall M
Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation.
Kovarik JM; Nashan B; Neuhaus P; Clavien PA; Gerbeau C; Hall ML; Korn A
Clin Pharmacol Ther; 2001 Apr; 69(4):201-9. PubMed ID: 11309548
[TBL] [Abstract][Full Text] [Related]
7. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
[TBL] [Abstract][Full Text] [Related]
8. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
10. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
11. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations.
Kovarik JM; Offner G; Broyer M; Niaudet P; Loirat C; Mentser M; Lemire J; Crocker JF; Cochat P; Clark G; Gerbeau C; Chodoff L; Korn A; Hall M
Transplantation; 2002 Oct; 74(7):966-71. PubMed ID: 12394838
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.
Mehra MR; Zucker MJ; Wagoner L; Michler R; Boehmer J; Kovarik J; Vasquez A
J Heart Lung Transplant; 2005 Sep; 24(9):1297-304. PubMed ID: 16143248
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.
Offner G; Broyer M; Niaudet P; Loirat C; Mentser M; Lemire J; Crocker JF; Cochat P; Clark G; Chodoff L; Korn A; Hall M
Transplantation; 2002 Oct; 74(7):961-6. PubMed ID: 12394837
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
Lawen JG; Davies EA; Mourad G; Oppenheimer F; Molina MG; Rostaing L; Wilkinson AH; Mulloy LL; Bourbigot BJ; Prestele H; Korn A; Girault D;
Transplantation; 2003 Jan; 75(1):37-43. PubMed ID: 12544868
[TBL] [Abstract][Full Text] [Related]
16. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts.
Kovarik J; Wolf P; Cisterne JM; Mourad G; Lebranchu Y; Lang P; Bourbigot B; Cantarovich D; Girault D; Gerbeau C; Schmidt AG; Soulillou JP
Transplantation; 1997 Dec; 64(12):1701-5. PubMed ID: 9422405
[TBL] [Abstract][Full Text] [Related]
17. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients.
Vester U; Kranz B; Testa G; Malagò M; Beelen D; Broelsch CE; Hoyer PF
Pediatr Transplant; 2001 Aug; 5(4):297-301. PubMed ID: 11472610
[TBL] [Abstract][Full Text] [Related]
19. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH
Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358
[TBL] [Abstract][Full Text] [Related]
20. Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm.
Kovarik JM; Gridelli BG; Martin S; Rodeck B; Melter M; Dunn SP; Merion RM; Tzakis AG; Alonso E; Bucuvalas J; Sharp H; Gerbeau C; Chodoff L; Korn A; Hall M
Pediatr Transplant; 2002 Jun; 6(3):224-30. PubMed ID: 12100507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
